1Shank PP, Gardocki JF, Streeter AJ, et al. An overview of the predinical aspects of topiramate:pharmacology,pharmacokinetics and mcchanimn of action. Epilepsia 2000；41 Suptl 1:3-9.
2Reife R, Pledger G, Wu SC. Topiramate as add-on therapy:pooled analysis of randomized controlled trials in adults. Epilepsia 2000；41 Suppl 1:66-71.
1Rosenfeld WE,Sachdeo RC,Faught RE,et al.Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizure: retrospective survey of open-label treatment[].Epilepsia.1997
2Shank RP,Gardocki JF,Streerter AJ,et al.An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics,and mechanism of action[].Epilepsia.2000
3Langtry HD,Gillis JC,Davis R.Topiramate: a review of its pharmacodynamic and pharmaokinetic properties and clinical efficacy in the management of epilepsy[].Drugs.1997
4Reife R,Pledger G,Wu SC.Topiramate as add-on therapy: pooled analysis of randomized controled trials in adults[].Epilepsia.2000
5Ormrod D,McClellan K.Topiramate: a review of its use in childhood epilepsy[].Paediatric Drugs.2001
6Rosenfeld WE.Topiramate: a review of preclinical, pharmacokinetic, and clinical data[].Clinical Therapeutics.1997
7Kerr MP.Topiramate: uses in people with an intellectual disability who have epilepsy[].Journal of Intellectual Disabilities.1998
8Sachdeo RC,Glauser TA,Ritter F,et al.A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome: Topiramate YL Study Group[].Neurology.1999
